Prophylactic Activated Factor VII in Liver Surgery
Author Information
Author(s): Chavez-Tapia Norberto C., Alfaro-Lara Roberto, Tellez-Avila Felix, Barrientos-Gutiérrez Tonatiuh, González-Chon Octavio, Mendez-Sanchez Nahum, Uribe Misael
Primary Institution: Obesity and Digestive Diseases Unit, Medica Sur Clinic and Foundation, Mexico City, Mexico
Hypothesis
Does prophylactic use of recombinant activated coagulation factor VII (rFVIIa) reduce mortality and bleeding in hepatobiliary surgery?
Conclusion
Prophylactic rFVIIa did not significantly affect mortality or bleeding outcomes in liver surgery.
Supporting Evidence
- Four randomized controlled trials were included in the analysis.
- No significant differences were found in mortality rates between rFVIIa and placebo.
- The requirement for red blood cell transfusions did not show significant benefits.
- An unexpected trend towards more serious adverse events was observed in liver transplantation patients treated with rFVIIa.
Takeaway
The study looked at whether a special medicine could help stop bleeding during liver surgery, but it didn't really work.
Methodology
The study included a systematic review and meta-analysis of randomized controlled trials comparing rFVIIa to placebo in liver surgery.
Potential Biases
All trials were at risk of bias due to unclear sequence generation and allocation concealment, and all were sponsored by the pharmaceutical industry.
Limitations
The number of trials included was small, limiting the ability to draw definitive conclusions.
Participant Demographics
Participants were adults aged 18 and older undergoing liver resection or transplantation, with most being cirrhotic patients.
Statistical Information
Confidence Interval
95% CI 0.35–2.63 for mortality
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website